Case Report

Acute Lymphoblastic Leukemia Arising in *CALR* Mutated Essential Thrombocythemia

Stephen E. Langabeer,¹ Karl Haslam,¹ David O'Brien,² Johanna Kelly,³ Claire Andrews,² Ciara Ryan,⁴ Richard Flavin,⁴ Patrick J. Hayden,² and Christopher L. Bacon²

¹Cancer Molecular Diagnostics, St. James's Hospital, Dublin 8, Ireland

²Department of Haematology, St. James's Hospital, Dublin 8, Ireland

³Department of Clinical Genetics, Our Lady's Children's Hospital, Dublin 12, Ireland

⁴Department of Histopathology, St. James's Hospital, Dublin 8, Ireland

Correspondence should be addressed to Stephen E. Langabeer; slangabeer@stjames.ie

Received 8 December 2015; Revised 6 January 2016; Accepted 10 January 2016

Academic Editor: Eduardo Arellano-Rodrigo

Copyright © 2016 Stephen E. Langabeer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The development of acute lymphoblastic leukemia in an existing myeloproliferative neoplasm is rare with historical cases unable to differentiate between concomitant malignancies or leukemic transformation. Molecular studies of coexisting *JAK2* V617F-positive myeloproliferative neoplasms and mature B cell malignancies indicate distinct disease entities arising in myeloid and lymphoid committed hematopoietic progenitor cells, respectively. Mutations of *CALR* in essential thrombocythemia appear to be associated with a distinct phenotype and a lower risk of thrombosis yet their impact on disease progression is less well defined. The as yet undescribed scenario of pro-B cell acute lymphoblastic leukemia arising in *CALR* mutated essential thrombocythemia is presented. Intensive treatment for the leukemia allowed for expansion of the original *CALR* mutated clone. Whether *CALR* mutations in myeloproliferative neoplasms predispose to the acquisition of additional malignancies, particularly lymphoproliferative disorders, is not yet known.

1. Introduction

Essential thrombocythemia (ET), together with polycythemia vera (PV), and primary myelofibrosis (PMF) are subtypes of the clinically and pathologically related Philadelphia chromosome-negative myeloproliferative neoplasms (MPN). ET is characterized by a sustained peripheral blood thrombocytosis and elevated numbers of mature, large megakaryocytes in the bone marrow and clinically by episodes of hemorrhage and/or thrombosis [1]. Identification of an acquired, clonal mutation has become a fundamental aspect of ET diagnosis [2] with identification of mutations of *JAK2*, *MPL*, and *CALR* likely to be incorporated into the revised World Health Organization diagnostic criteria for this MPN [3].

Although a relatively indolent disorder, there exists a potential for ET patients to transform to a myelofibrotic or leukemic phase. While most leukemic transformations in MPN resemble acute myeloid leukemia [4], transformations

to, or coexistence of, an acute lymphoblastic leukemia (ALL) of either B cell or T cell phenotype are uncommon but have been documented in PV [5–10], ET [11–14], PMF [15–17], post-PV MF [18], and MPN unclassified [19] which usually become apparent following treatment with alkylating agents or radioactive phosphorus. Whether all these cases represent a true clonal evolution of the MPN or are the manifestation of two separate diseases remains unresolved in most historical instances. Clinical management of such cases is complex requiring consideration of both pathologies.

From the initial report of *CALR* mutations in MPN, it has become increasingly evident that *CALR*-positive ET patients possess a different phenotype from their *JAK2* V617F-positive counterparts with a younger age, male predominance, higher platelet count, lower hemoglobin, lower leucocyte count, and, perhaps most clinically relevant, a lower risk of thrombosis [20–25]. However, the impact of *CALR* mutations on myelofibrotic and leukemic transformation is less well

defined [21–23]. Furthermore, an increased risk of lymphoid neoplasms, particularly mature B cell malignancies such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma, has been reported in MPN patients compared to the general population [26, 27] suggesting a pathophysiological link between the two diseases. A specific genetic cause or microenvironmental, inflammatory interaction for this predisposition has yet to be identified. A case is described of a hitherto unreported development of ALL in a patient with *CALR* mutated ET.

2. Case Report

A 65-year-old female presented with an incidentally detected thrombocytosis in 2012. Initial hematological investigation showed a hemoglobin of 13.5 g/dL, white cell count of $6.2 \times 10^9/L$, and platelets of $674 \times 10^9/L$ with platelet anisocytosis and giant platelets on the peripheral blood (PB) film. The bone marrow (BM) aspirate and biopsy were both slightly hypercellular with increased numbers of clustering megakaryocytes (Figure 1(a)) and no increase in reticulin fibrosis consistent with a diagnosis of ET. Cytogenetic analysis was not performed at this time. The *JAK2* V617F mutation was not detected by allele-specific PCR [28]. The patient was commenced on aspirin and hydroxyurea to bring the platelet count within normal range. Retrospective fragment length analysis for *CALR* mutations [29] on the archived, diagnostic, unselected, and PB DNA demonstrated the presence of a type 1 mutation (52-bp deletion, p.L367fs*46) at an allele burden of 49% (Figure 1(b)).

Three and a half years after ET diagnosis, the patient presented with left hip pain, hemoglobin of 12.3 g/dL, white cell count of $5.3 \times 10^9/L$, platelets of $261 \times 10^9/L$, and a lactate dehydrogenase of 1186 IU/L. Macrocytosis, nucleated red blood cells, myelocytes, and 2% blasts of lymphoid appearance were observed on the PB film. In the BM aspirate, blasts with a high N/C ratio with prominent cytoplasmic vacuolation and blebbing accounted for 53% of nucleated cells morphologically (Figure 1(c)) and were CD34+, CD19+, HLA DR+, CD20+, CD38+, TdT+, and CD10– by multicolor flow cytometry and CD34+, PAX5+, TdT+, CD10–, and MPO– by immunohistochemistry, consistent with a diagnosis of pro-B ALL. There was no evidence of increased reticulin fibrosis. Cytogenetic analysis demonstrated a near-triploid clone of 60~67, XXX, +X, +1, –3, –7, +8, –9, add(14)(p11), –15, –16, –17, +18, +18, +19, –20, and +21 [cp7]. The unselected BM *CALR* mutant allele burden at the time of ALL diagnosis was 51%. The patient commenced induction chemotherapy with dexamethasone, idarubicin, vincristine, and methotrexate attaining a morphological, cytogenetic, and immunophenotypic remission. Recovery from induction was associated with a rising platelet count peaking at $1163 \times 10^9/L$ and an unselected BM *CALR* mutant allele burden of 67%. Following a course of consolidation chemotherapy the patient remained in morphological, cytogenetic, and immunophenotypic remission, with increased megakaryocytes still evident on the BM biopsy (Figure 1(d)). The recovery platelet count peaked at $470 \times 10^9/L$ with an unselected BM *CALR* mutant allele burden of

72% (Figure 1(e)). The patient was unsuitable for allogeneic hematopoietic stem cell transplantation (AHSCT) and she remains on treatment for both ALL and ET.

3. Discussion

The development of ALL in patients with an existing MPN, whether concomitant or representing a true leukemic evolution, has been sporadically documented [5–19]. In the pre-*JAK2* V617F era, only cytogenetic evidence was available to support the existence of distinct entities [30]. However, cell sorting and mutational analysis of hematopoietic stem and progenitor cells in ET and PV cases with coexisting CLL have demonstrated the absence of the *JAK2* V617F and, in one previous case, a *CALR* mutation, in the lymphoid compartment [31–34]. Similar investigations in cases of ALL arising in MPN have distinguished separate clonal origins of the two hematopoietic malignancies [35, 36] therefore weakening the argument for lymphoblastic transformation. However, it remains possible that the ALL could be derived from a malignant subclone prior to the acquisition of the *CALR* mutation. Low numbers of circulating peripheral blood lymphoblasts prohibited such a selection procedure in this case.

Recent evidence suggests that the two most common *CALR* mutation types might influence the MPN phenotype and disease course: type 1 mutations appear to be associated with PMF phenotype whereas type 2 mutations (a 5-bp insertion, p.K385fs*47) are more commonly observed in ET [37–39]. Type 1 *CALR* mutations in ET, as evident in the patient described herein, are also associated with a higher risk of myelofibrotic transformation although the biological mechanism(s) for this have yet to be clarified: impaired calcium signalling and calcium binding activity to mutant *CALR* protein have been preferentially demonstrated in type 1 *CALR* mutated MPN [39]. At present there is no evidence of equivalence of mutated *CALR* allele burden between peripheral blood and bone marrow; however, of particular note is the mutated *CALR* allele burden after ALL treatment. Mutant *CALR* allele burdens greater than 50% are rare in ET and PMF at diagnosis suggesting the majority of mutations are heterozygous. The relatively high mutant *CALR* allele burdens after ALL treatment might represent loss of heterozygosity in at least some mutant clones, analogous to that observed in the progression of *JAK2* V617F-positive PV [40].

Hydroxyurea is commonly used for the long term treatment of MPN and is well tolerated in the majority of patients. Some early debate suggested that hydroxyurea might contribute to or hastens leukemic transformation; however it was unsure whether transformation was part of the natural history in such instances [41]. Several large studies have subsequently confirmed that hydroxyurea is not associated with myelofibrotic or leukemic transformation in MPN [42–45]. Some studies have reported an increased risk of other cancers, including hematological malignancies, in MPN with myelosuppressive treatment speculated to be a potential cause. Epidemiological evidence of this increased cancer incidence is supported by noting malignancies prior to MPN diagnosis thus eliminating the influence of MPN related treatment [46].

FIGURE 1: (a) Bone marrow trephine biopsy at diagnosis of essential thrombocythemia (Hematoxylin and Eosin; magnification ×20); (b) fragment length detection of the *CALR* mutation; (c) bone marrow aspirate at diagnosis of acute lymphoblastic leukemia; (d) bone marrow trephine biopsy following two courses of chemotherapy (Hematoxylin and Eosin; magnification ×20); (e) mutant *CALR* allele burdens.

The cooccurrence of MPN and solid tumors may be attributed to the presence of a predisposing *TERT* polymorphism [47]. Another possible common denominator in MPN occurring in conjunction with other malignancies is chronic inflammation, able to potentiate each other's existence and progression [48].

While the coexistence of MPN and mature B cell lymphoproliferative disorders has been documented, cases of MPN and ALL are extremely scarce. We describe, to the best of our knowledge, the clinical course of the first case of pro-B ALL arising in a patient with *CALR* mutated ET. The persistence of the *CALR* mutated clone following treatment for ALL suggests that long term eradication of both diseases would be only achievable with AHSCT.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

- [1] J. Thiele, H. M. Kvasnicka, A. Orazi, A. Tefferi, and H. Gisslinger, "Essential thrombocythaemia," in *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*, pp. 48–50, International Agency for Research on Cancer, Lyon, France, 2008.
- [2] S. E. Langabeer, H. Andrikovics, J. Asp et al., "Molecular diagnostics of myeloproliferative neoplasms," *European Journal of Haematology*, vol. 95, no. 4, pp. 270–279, 2015.
- [3] T. Barbui, J. Thiele, A. M. Vannucchi, and A. Tefferi, "Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis," *Blood Cancer Journal*, vol. 5, no. 8, article e337, 2015.
- [4] M. Czader and A. Orazi, "Acute myeloid leukemia and other types of disease progression in myeloproliferative neoplasms," *American Journal of Clinical Pathology*, vol. 144, no. 2, pp. 188–206, 2015.
- [5] R. Hoffman, S. Estren, S. Kopel, S. M. Marks, and R. P. McCaffrey, "Lymphoblastic-like leukemic transformation of polycythemia vera," *Annals of Internal Medicine*, vol. 89, no. 1, p. 71, 1978.
- [6] T. A. Braich, T. M. Grogan, M. J. Hicks, and B. R. Greenberg, "Terminal lymphoblastic transformation in polycythemia vera," *The American Journal of Medicine*, vol. 80, no. 2, pp. 304–306, 1986.
- [7] R. Aitchison, A. J. Black, and M. F. Greaves, "Polycythaemia rubra vera transforming to acute lymphoblastic leukaemia," *Clinical and Laboratory Haematology*, vol. 9, no. 2, pp. 201–204, 1987.
- [8] J. R. Neilson, W. N. Patton, M. D. Williams, E. E. Mayne, and B. J. Boughton, "Polycythaemia rubra vera transforming to acute lymphoblastic leukaemia with a common immunophenotype," *Journal of Clinical Pathology*, vol. 47, no. 5, pp. 471–472, 1994.
- [9] Y. Arai, M. Masuda, T. Okamura, M. Wada, T. Motoji, and H. Mizoguchi, "Polycythemia vera progressing to acute lymphoblastic leukemia after 13 years," *Rinsho Ketsueki*, vol. 37, no. 12, pp. 1405–1409, 1996.
- [10] M. Camós, F. Cervantes, S. Montoto, J. C. Hernández-Boluda, N. Villamor, and E. Montserrat, "Acute lymphoid leukemia following polycythemia vera," *Leukemia & Lymphoma*, vol. 32, no. 3–4, pp. 395–398, 1999.
- [11] A. M. O'Hea, W. Erber, N. T. J. O'Connor, and C. Bunch, "Acute transformation of essential thrombocythaemia: report of two cases," *Journal of Clinical Pathology*, vol. 39, no. 12, pp. 1296–1298, 1986.
- [12] P. T. Murphy, M. Sivakumaran, F. van Rhee, A. E. Watmore, and V. E. Mitchell, "Acute lymphoblastic transformation of essential thrombocythaemia," *British Journal of Haematology*, vol. 89, no. 4, pp. 921–922, 1995.
- [13] K. K. Woronzoff-Dashkoff and C. E. Litz, "Acute lymphoblastic leukemia in a case of essential thrombocythemia," *American Journal of Clinical Pathology*, vol. 106, no. 2, pp. 206–208, 1996.
- [14] L. C. Berkahn, J. Nelson, P. A. Ockelford, and P. J. Browett, "Transformation of essential thrombocythaemia to T cell acute lymphoblastic leukaemia," *Leukemia and Lymphoma*, vol. 20, no. 3–4, pp. 347–349, 1995.
- [15] S. P. Shaheen II, S. S. Talwalkar, R. Simons, and L. Yam, "Acute lymphoblastic leukemic transformation in a patient with chronic idiopathic myelofibrosis and paroxysmal nocturnal hemoglobinuria," *Archives of Pathology & Laboratory Medicine*, vol. 129, no. 1, pp. 96–99, 2005.
- [16] M. Sever, J. L. Jorgensen, I. Gurevich, M. Pinheiro, and S. Verstovsek, "Primary myelofibrosis with concurrent precursor T-cell lymphoblastic lymphoma of the spleen in a 26-year-old patient," *Leukemia Research*, vol. 33, no. 11, pp. e186–e188, 2009.
- [17] V. Jurisic, N. Colovic, T. Terzic, V. Djordjevic, and M. Colovic, "Transformation of primary myelofibrosis with 20q-in Philadelphia-positive acute lymphoblastic leukemia: case report and review of literature," *Pathology Research and Practice*, vol. 208, no. 7, pp. 420–423, 2012.
- [18] M. Ohanian, V. Leventaki, S. Verstovsek et al., "Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity," *Leukemia and Lymphoma*, vol. 53, no. 9, pp. 1839–1841, 2012.
- [19] U. Bacher, T. Haferlach, W. Kern, H.-D. Harich, S. Schnittger, and C. Haferlach, "A case of chronic myeloproliferative syndrome followed by precursor T-cell acute lymphoblastic leukemia," *Cancer Genetics & Cytogenetics*, vol. 175, no. 1, pp. 52–56, 2007.
- [20] T. Klampfl, H. Gisslinger, A. S. Harutyunyan et al., "Somatic mutations of calreticulin in myeloproliferative neoplasms," *The New England Journal of Medicine*, vol. 369, no. 25, pp. 2379–2390, 2013.
- [21] E. Rumi, D. Pietra, V. Ferretti et al., "JAK2 or *CALR* mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes," *Blood*, vol. 123, no. 10, pp. 1544–1551, 2014.
- [22] G. Rotunno, C. Mannarelli, P. Guglielmelli et al., "Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia," *Blood*, vol. 123, no. 10, pp. 1552–1555, 2014.
- [23] A. Tefferi, E. A. Wassie, T. L. Lasho et al., "Calreticulin mutations and long-term survival in essential thrombocythemia," *Leukemia*, vol. 28, no. 12, pp. 2300–2303, 2014.
- [24] H. Andrikovics, T. Krahling, K. Balassa et al., "Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations," *Haematologica*, vol. 99, no. 7, pp. 1184–1190, 2014.
- [25] A. P. Trifa, R. A. Popp, A. Cucianu et al., "*CALR* versus *JAK2* mutated essential thrombocythaemia—a report on 141 patients," *British Journal of Haematology*, vol. 168, no. 1, pp. 151–153, 2015.

- [26] A. M. Vannucchi, G. Masala, E. Antonioli et al., "Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms," *Cancer Epidemiology Biomarkers and Prevention*, vol. 18, no. 7, pp. 2068–2073, 2009.
- [27] P. Miltiades, E. Lamprianidou, I. K. Kerzeli et al., "Three-fold higher frequency of circulating chronic lymphocytic leukemia-like B-cell clones in patients with Ph-myeloproliferative neoplasms," *Leukemia Research*, vol. 39, no. 11, pp. 1159–1165, 2015.
- [28] E. J. Baxter, L. M. Scott, P. J. Campbell et al., "Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders," *The Lancet*, vol. 365, no. 9464, pp. 1054–1061, 2005.
- [29] K. Haslam, S. E. Langabeer, K. Molloy, M. F. McMullin, and E. Conneally, "Assessment of CALR mutations in myelofibrosis patients, post-allogeneic stem cell transplantation," *British Journal of Haematology*, vol. 166, no. 5, pp. 800–802, 2014.
- [30] J. Anastasi, M. J. Pettenati, M. M. Le Beau, H. C. Kwaan, and S. C. Weil, "Acute lymphoblastic leukemia in a patient with longstanding polycythemia vera: cytogenetic analysis reveals two distinct abnormal clones," *American Journal of Hematology*, vol. 29, no. 1, pp. 33–37, 1988.
- [31] L. Henry, S. Carillo, E. Jourdan, A. Arnaud, S. Brun, and T. Lavabre-Bertrand, "Association of essential thrombocythemia and chronic lymphocytic leukemia: absence of the V617F JAK2 mutation in the lymphoid compartment," *American Journal of Hematology*, vol. 82, no. 6, pp. 500–501, 2007.
- [32] C. Musolino, A. Allegra, G. Penna et al., "Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders," *Acta Haematologica*, vol. 122, no. 1, pp. 46–49, 2009.
- [33] S. Swierczek, J. Nausova, J. Jelinek et al., "Concomitant JAK2 V617F-positive polycythemia vera and B-cell chronic lymphocytic leukemia in three patients originating from two separate hematopoietic stem cells," *American Journal of Hematology*, vol. 88, no. 2, pp. 157–158, 2013.
- [34] M. E. Salama, S. I. Swierczek, T. Tashi, C. A. Warby, N. S. Reading, and J. T. Prchal, "Calreticulin mutated prefibrotic-stage myelofibrosis and PMF represent an independent clone from coexisting CLL," *Blood*, vol. 124, no. 10, pp. 1691–1692, 2014.
- [35] Y. Nagai, M. Kawahara, N. Sugino et al., "A case of minor BCR-ABL1 positive acute lymphoblastic leukemia following essential thrombocythemia and originating from a clone distinct from that harboring the JAK2-V617F mutation," *Experimental Hematology & Oncology*, vol. 3, no. 1, article 6, 2014.
- [36] J. Tao, X. Zhang, J. Lancet et al., "Concurrence of B-lymphoblastic leukemia and myeloproliferative neoplasm with copy neutral loss of heterozygosity at chromosome 1p harboring a MPL W515S mutation," *Cancer Genetics*, vol. 207, no. 10–12, pp. 489–494, 2014.
- [37] A. Tefferi, E. A. Wassie, P. Guglielmelli et al., "Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients," *American Journal of Hematology*, vol. 89, no. 8, pp. E121–E124, 2014.
- [38] X. Cabagnols, J. P. Defour, V. Ugo et al., "Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocythemia: relevance for disease evolution," *Leukemia*, vol. 29, no. 1, pp. 249–252, 2015.
- [39] D. Pietra, E. Rumi, W. Ferretti et al., "Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms," *Leukemia*, 2015.
- [40] A. M. Vannucchi, E. Antonioli, P. Guglielmelli, A. Pardanani, and A. Tefferi, "Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal," *Leukemia*, vol. 22, no. 7, pp. 1299–1307, 2008.
- [41] T. Barbui, "The leukemia controversy in myeloproliferative disorders: is it a natural progression of the disease, a secondary sequel of therapy, or a combination of both?" *Seminars in Hematology*, vol. 41, no. 2, supplement 2, pp. 15–17, 2004.
- [42] M. L. Randi, E. Ruzzon, G. Luzzatto, F. Tezza, A. Girolami, and F. Fabris, "Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders," *Haematologica*, vol. 90, no. 2, pp. 261–262, 2005.
- [43] N. Gangat, A. P. Wolanskyj, R. F. McClure et al., "Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients," *Leukemia*, vol. 21, no. 2, pp. 270–276, 2007.
- [44] F. Palandri, L. Catani, N. Testoni et al., "Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy," *American Journal of Hematology*, vol. 84, no. 4, pp. 215–220, 2009.
- [45] M. Björkholm, Å. R. Derolf, M. Hultcrantz et al., "Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms," *Journal of Clinical Oncology*, vol. 29, no. 17, pp. 2410–2415, 2011.
- [46] H. Pettersson, H. Knutsen, E. Holmberg, and B. Andréasson, "Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis," *European Journal of Haematology*, vol. 94, no. 2, pp. 152–156, 2015.
- [47] T. Krahling, K. Balassa, K. P. Kiss et al., "Co-occurrence of myeloproliferative neoplasms and solid tumors is attributed to a synergism between cytoreductive therapy and the common TERT polymorphism rs2736100," *Cancer Epidemiology Biomarkers & Prevention*, vol. 25, no. 1, pp. 98–104, 2016.
- [48] S. Hermouet, E. Bigot-Corbel, and B. Gardie, "Pathogenesis of myeloproliferative neoplasms: role and mechanisms of chronic inflammation," *Mediators of Inflammation*, vol. 2015, Article ID 145293, 16 pages, 2015.